The most prominent COVID-19 variant circulating in the United States right now is XFG.1.1, which accounted for roughly 32% of sequenced cases in the two-week period ending April 11, 2026, according to CDC surveillance data. Like every dominant strain since late 2023, XFG.1.1 descends from the BA.2.86 lineage and its Omicron-era offspring. Globally, the WHO still classifies JN.1 and its descendants as variants of interest, with no variants currently labeled “variants of concern.”
How Today’s Variants Evolved
The current landscape traces back to BA.2.86, which picked up a mutation called L455S in its spike protein and became JN.1 by late 2023. JN.1 replicated more slowly than its parent, but it was significantly better at dodging antibodies people had built up from earlier infections. That trade-off, slower replication but stronger immune evasion, was enough to make JN.1 dominant worldwide.
From JN.1, the virus branched into KP.2 and KP.3, sometimes nicknamed the “FLiRT” variants after two of their key spike mutations (F456L and R346T). KP.2 combined better replication with greater resistance to antibodies generated by JN.1 infections. KP.3 then pushed replication fitness even higher thanks to an additional mutation (Q493E), while maintaining similar immune evasion. Each step gave the newer lineage a competitive edge, allowing it to displace its predecessor within weeks.
Subvariants like KP.3.1.1 and XEC followed, further refining immune evasion. XFG.1.1, the current front-runner in the U.S., sits on this same evolutionary branch. The pattern is consistent: small, recurrent mutations in the spike protein’s receptor-binding domain keep fine-tuning how well the virus enters human cells and how effectively it slips past existing immunity.
Symptoms and Incubation Period
Symptoms of current variants look much the same as they have throughout the Omicron era. The CDC lists fever, cough, sore throat, congestion, fatigue, headache, muscle aches, and loss of taste or smell as the primary signs. Symptoms can appear anywhere from 2 to 14 days after exposure, but with Omicron-lineage strains the typical window is shorter: most people develop symptoms 3 to 6 days after contact. Illness generally lasts up to 10 days, though some people experience lingering symptoms beyond that.
There is no evidence that XFG.1.1 or its recent predecessors cause a distinctly different symptom profile compared to earlier Omicron subvariants. The severity of any individual infection still depends heavily on vaccination status, prior infections, age, and underlying health conditions.
How Well the Current Vaccine Works
The 2024-2025 COVID vaccine formula targets the JN.1 lineage, the ancestor of today’s circulating strains. CDC data from September 2024 through January 2025 showed that among immunocompetent adults 65 and older, the updated vaccine reduced COVID-related hospitalization by about 45% in the first four months after the shot. For older adults with weakened immune systems, protection against hospitalization was around 40% over the same period.
Hospitalization rates during that study window were relatively low, which made it difficult to calculate how well the vaccine protected against the most severe outcomes like ICU admission or death. Still, a 40-45% reduction in hospitalization is meaningful for high-risk groups, especially when layered on top of whatever residual immunity people carry from prior infections and earlier vaccinations.
Testing Accuracy With Newer Strains
At-home rapid antigen tests still detect current variants, but their sensitivity has important limitations. In a CDC study comparing rapid tests to the gold-standard PCR test, overall sensitivity was 47%. That number climbed to 56% on days when someone had active symptoms, and hit 77% on days with fever. On days with no symptoms, sensitivity dropped to just 18%.
The practical takeaway: a positive rapid test is reliable, but a negative result doesn’t rule out infection, especially in the first day or two of illness or if you’re not yet symptomatic. Testing on day 3 after symptom onset tends to catch the most cases. If your first test is negative but you feel sick, repeat it 24 to 48 hours later. People at high risk for severe illness should consider getting a PCR test through a healthcare provider, since those tests are substantially more sensitive.
What Makes These Variants Harder to Neutralize
The reason new subvariants keep emerging comes down to a handful of recurring mutations in the spike protein, specifically in the region that latches onto human cells. Mutations at positions like R346T, L455S, F456L, and Q493E each nudge the virus in one of two directions: better immune evasion or faster replication. Sometimes a single mutation does both.
Lab studies using human airway cells show that each successive variant from BA.2.86 onward has found a slightly better balance between these two traits. KP.2 was harder to neutralize with antibodies from JN.1-era infections. KP.3 replicated faster than KP.2 while staying equally hard to neutralize. This incremental optimization is what drives one lineage to replace another every few months. It also explains why vaccine formulas need periodic updates, since antibodies trained against an older spike shape become less effective as these mutations accumulate.
Treatments Still in Play
The standard antiviral treatments available since 2022 remain the primary options for people who test positive and are at elevated risk for severe disease. Researchers are also developing new classes of entry inhibitors designed to block the virus from getting into cells in the first place. Early lab work on compounds tested against KP.3.1.1 and XEC has shown promising results, with some experimental analogs outperforming their parent compounds. These are still in preclinical stages, but they represent an effort to stay ahead of the virus’s shifting spike protein.
For now, the most important factor in outcomes remains timing. Antiviral treatment works best when started within the first few days of symptoms, which makes prompt testing critical for anyone in a high-risk group.